Ocular pharmacokinetics (PK) or rhuFab V2 following intravitreal (ITV) administration in cynomolgus monkeys.

被引：0
|
作者：
Gaudreault, J
Fei, D
Suboc, P
Chan, P
Nelson, J
Lappin, P
Hartmangruber, M
Rusit, J
O'Neill, C
Hsei, V
机构：
[1] Genentech Inc, Pharmacokinet & Metab, S San Francisco, CA USA
[2] Genentech Inc, Bioanalyt Methods Developism, San Francisco, CA 94080 USA
[3] Sierra Biomed, Sparks, NY USA
[4] Genentech Inc, Assay Serv, S San Francisco, CA USA
[5] Genentech Inc, Toxicol, S San Francisco, CA USA
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2001年 / 42卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
5000
引用
收藏
页码：S933 / S933
页数：1
相关论文
共 50 条
  • [1] Ocular pharmacokinetics and antipermeability effect of rhuFab V2 in animals
    Gaudreault, J
    Reich, M
    Arata, A
    Rusit, J
    Pelletier, N
    Shiu, V
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 : U411 - U411
  • [2] Population, pharmacokinetics (PK) of bevacizumab (BV) in cynomolgus monkeys.
    Gaudreault, J
    Siguenza, P
    O'Neill, C
    Torres, E
    Vogel, J
    Hsei, V
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P97 - P97
  • [3] The pharmacokinetics and pharmacodynamics of OPG following single dose administration in cynomolgus monkeys.
    Martin, SW
    Sommers, JS
    Watson, AM
    Young, JD
    Dunstan, CR
    JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 : S399 - S399
  • [4] Safety evaluation of intravitreal administration of rhuFab VEGF in cynomolgus monkeys for 3 months.
    O'Neill, CA
    Christian, B
    Murphy, CJ
    Miller, P
    VerHoeve, J
    Leedle, R
    Dubielzig, RR
    Beyer, JC
    Albert, DM
    Davis, M
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2000, 41 (04) : S142 - S142
  • [5] Safety evaluation of differing schedules of intravitreal administration of rhuFab VEGF in Cynomolgus Monkeys for two months.
    O'Neill, CA
    Miller, P
    Christian, B
    Leedle, R
    Dubielzig, R
    Beyer, JC
    Nork, TM
    Wabers, H
    Neider, M
    Murphy, CJ
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2001, 42 (04) : S225 - S225
  • [6] RhuFab V2 in wet AMD - 6 month continued improvement following multiple intravitreal injections
    Heier, JS
    Sy, JR
    McCluskey, ER
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 : U267 - U267
  • [7] Bone mineral density is increased following monthly administration of AMG 162 in cynomolgus monkeys.
    Atkinson, JE
    Cranmer, P
    Mohr, S
    Niehaus, M
    Jerome, CP
    Cosenza, ME
    Dunstan, CR
    DePaoli, AM
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S96 - S96
  • [8] Vitreal pharmacokinetics of rhuFab V2 in rabbits using a non-invasive method
    Gaudreault, J
    Escandon, E
    Maruoka, M
    Reich, M
    Li, D
    Hsei, V
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2002, 43 : U654 - U654
  • [9] Effects of unoprostone isopropyl in ocular blood flow decrease induced by systemic vasoconstrictor administration in cynomolgus monkeys.
    Questel, I
    Pages, C
    Lambrou, GN
    Percicot, CP
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2000, 41 (04) : S560 - S560
  • [10] Erythropoiesis equivalence, pharmacolkinetics and antibody analysis following subcutaneous and intravenous Hematide™ administration in cynomolgus monkeys.
    Woodburn, Kathryn W.
    Schatz, Peter J.
    Fong, Kei-lai
    Beaumier, Paul L.
    BLOOD, 2006, 108 (11) : 338A - 339A
12345